SG11201804360XA - Mat2a inhibitors for treating mtap null cancer - Google Patents
Mat2a inhibitors for treating mtap null cancerInfo
- Publication number
- SG11201804360XA SG11201804360XA SG11201804360XA SG11201804360XA SG11201804360XA SG 11201804360X A SG11201804360X A SG 11201804360XA SG 11201804360X A SG11201804360X A SG 11201804360XA SG 11201804360X A SG11201804360X A SG 11201804360XA SG 11201804360X A SG11201804360X A SG 11201804360XA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- mat2a
- mtap
- massachusetts
- publication
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/02—Halogenated hydrocarbons
- A61K31/025—Halogenated hydrocarbons carbocyclic
- A61K31/03—Halogenated hydrocarbons carbocyclic aromatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -' Organization International Bureau ... .... 0Y)1 (43) International Publication Date .... ......) 8 June 2017 (08.06.2017) WI P0 I P CT ID Hit (10) WO 111111111111111111IIIIIIII International II 2017/096165 Publication IIIIIIIIIIIIIIIIIIIIIIIIIIIIII Al Number RIO IIII IIIIIIII (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/015 (2006.01) A61K 31/505 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 45/00 (2006.01) A61P 35/00 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, (21) International Application Number: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US2016/064619 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (22) International Filing Date: KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, 2 December 2016 (02.12.2016) MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (25) Filing Language: English SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (26) Publication Language: English TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 62/262,750 3 December 2015 (03.12.2015) US (84) Designated States (unless otherwise indicated, for every 62/297,572 19 February 2016 (19.02.2016) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, (71) Applicant: AGIOS PHARMACEUTICALS, INC. TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, [US/US]; 88 Sidney Street, Cambridge, Massachusetts TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, 02139 (US). DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, (72) Inventors: MARJON, Katya; 117 Maskwonicut Street, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, Sharon, Massachusetts 02067 (US). CHOE, Sung Eun; 12 Kimball Road, Lexington, Massachusetts 02421 (US). GW, KM, ML, MR, NE, SN, TD, TG). Published: (74) Agents: PERDOK, Monique M., Reg. No. 42,989 et al.; 21(3)) P.O. Box 2938, Minneapolis, Minnesota 55402 (US). — with international search report (Art (54) Title: MAT2A INHIBITORS FOR TREATING MTAP NULL CANCER (57) : The present invention provides diagnostic and prognostic methods for predicting the effectiveness of MAT2A inhibitor. AG1-512 treatment of a cancer patient with a Methods are for predicting the sensitivity of tu- .40>o , ... 150 provided 1 ;. mor cell growth to inhibition by a MAT2A inhibitor, 1 comprising assessing whether the tumor cell is absent an MTAP MTAP whereby cells that are MTAP null are sensit- wt gene : ive to inhibition by MAT2A inhibitors. ,....- I tX9 ,,,, ,,,,„...„ \; —.1.—.4.\...$ . ‘ ;., I . 1 1: MIA? nu 1 eo i 0 io 1.0 10 4 10 104 1O .4t \"4 1-1 C\ C It - -- 1-1 C ei io 1-1 ilA FIGUREA . 2). M S O
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562262750P | 2015-12-03 | 2015-12-03 | |
| US201662297572P | 2016-02-19 | 2016-02-19 | |
| PCT/US2016/064619 WO2017096165A1 (en) | 2015-12-03 | 2016-12-02 | Mat2a inhibitors for treating mtap null cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201804360XA true SG11201804360XA (en) | 2018-06-28 |
Family
ID=57614465
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201804360XA SG11201804360XA (en) | 2015-12-03 | 2016-12-02 | Mat2a inhibitors for treating mtap null cancer |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20180371551A1 (en) |
| EP (1) | EP3383375A1 (en) |
| JP (2) | JP6877429B2 (en) |
| KR (1) | KR20180100125A (en) |
| CN (1) | CN108601752A (en) |
| AU (1) | AU2016364855B2 (en) |
| CA (1) | CA3006743A1 (en) |
| EA (1) | EA201891304A1 (en) |
| IL (1) | IL259773A (en) |
| MX (1) | MX2018006781A (en) |
| SG (1) | SG11201804360XA (en) |
| WO (1) | WO2017096165A1 (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3795215A1 (en) | 2012-05-30 | 2021-03-24 | Chugai Seiyaku Kabushiki Kaisha | Target tissue-specific antigen-binding molecule |
| MX2016007312A (en) | 2013-12-04 | 2017-01-13 | Chugai Pharmaceutical Co Ltd | Antigen-binding molecules, the antigen-binding activity of which varies according to the concentration of compounds, and libraries of said molecules. |
| US11376256B2 (en) | 2018-07-19 | 2022-07-05 | Agency For Science, Technology And Research | Method of treating a methionine-dependent cancer |
| MX2021006841A (en) | 2018-12-10 | 2021-07-02 | Ideaya Biosciences Inc | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors. |
| WO2020189748A1 (en) * | 2019-03-19 | 2020-09-24 | 中外製薬株式会社 | Antigen-binding molecule containing antigen-binding domain of which binding activity to antigen is changed depending on mta, and library for obtaining said antigen-binding domain |
| WO2021023609A1 (en) * | 2019-08-02 | 2021-02-11 | Glaxosmithkline Intellectual Property Development Limited | Combination of a type i protein arginine methyltransferase (type i prmt) inhibitor and a methionine adenosyltransferase ii alpha (mat2a) inhibitor |
| WO2021158792A1 (en) * | 2020-02-04 | 2021-08-12 | Agios Pharmaceuticals, Inc. | Methods of treating autoimmune or inflammatory diseases or disorders |
| TW202227082A (en) * | 2020-08-12 | 2022-07-16 | 美商施維雅製藥有限公司 | Combination therapies for use in treating cancer |
| BR112023025360A2 (en) * | 2021-06-02 | 2024-02-20 | Ideaya Biosciences Inc | USE OF A METHIONINE ADENOSYLTRANSFERASE II ALPHA (MAT2A) INHIBITOR AND A PROTEIN ARGININE METHYLTRANSFERASE TYPE II (PRMT TYPE II) INHIBITOR, USE OF A COMPOUND A, COMBINATION PRODUCTS AND MAT2A INHIBITORS |
| CN113476450B (en) * | 2021-08-10 | 2023-04-28 | 江南大学 | Application of EPZ015666 in preparation of medicine for preventing and treating vascular intimal hyperplasia diseases |
| CN114028572B (en) * | 2021-11-30 | 2022-11-25 | 清华大学 | Novel use of MAT2A inhibitor for treating asthma |
Family Cites Families (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4503035B1 (en) | 1978-11-24 | 1996-03-19 | Hoffmann La Roche | Protein purification process and product |
| US4530901A (en) | 1980-01-08 | 1985-07-23 | Biogen N.V. | Recombinant DNA molecules and their use in producing human interferon-like polypeptides |
| US5231176A (en) | 1984-08-27 | 1993-07-27 | Genentech, Inc. | Distinct family DNA encoding of human leukocyte interferons |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4868103A (en) | 1986-02-19 | 1989-09-19 | Enzo Biochem, Inc. | Analyte detection by means of energy transfer |
| US4843155A (en) | 1987-11-19 | 1989-06-27 | Piotr Chomczynski | Product and process for isolating RNA |
| GB8827305D0 (en) | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
| US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
| EP0552108B1 (en) | 1992-01-17 | 1999-11-10 | Lakowicz, Joseph R. | Energy transfer phase-modulation fluoro-immunoassay |
| ATE419355T1 (en) | 1992-02-06 | 2009-01-15 | Novartis Vaccines & Diagnostic | MARKER FOR CANCER AND BIOSYNTHETIC BINDING PROTEIN FOR IT |
| US6177401B1 (en) | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
| US5455258A (en) | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
| US5942393A (en) | 1993-12-29 | 1999-08-24 | The Regents Of The University Of California | Method for the detection of the presence or absence of methylthioadenosine phosphorylase (MTASE) in a cell sample by detection of the presence or absence of MTASE encoding nucleic acid in the cell sample |
| IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
| US5863949A (en) | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
| PT821671E (en) | 1995-04-20 | 2001-04-30 | Pfizer | ARYLSULFONYL HYDROXAMIC ACID DERIVATIVES AS MMP AND TNF INHIBITORS |
| US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
| GB9520822D0 (en) | 1995-10-11 | 1995-12-13 | Wellcome Found | Therapeutically active compounds |
| ES2206602T3 (en) | 1995-10-23 | 2004-05-16 | The Children's Medical Center Corporation | INHIBITING THERAPEUTIC COMPOUNDS AND METHODS OF ANGIOGENESIS. |
| US5854033A (en) | 1995-11-21 | 1998-12-29 | Yale University | Rolling circle replication reporter systems |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| DE69624081T2 (en) | 1995-12-20 | 2003-06-12 | Hoffmann La Roche | Matrix metalloprotease inhibitors |
| US6291455B1 (en) | 1996-03-05 | 2001-09-18 | Zeneca Limited | 4-anilinoquinazoline derivatives |
| JPH11512750A (en) | 1996-06-27 | 1999-11-02 | ファイザー インク． | Derivatives of 2- (2-oxo-ethylidene) -imidazolidin-4-one and their use as farnesyl protein transferase inhibitors |
| EP0818442A3 (en) | 1996-07-12 | 1998-12-30 | Pfizer Inc. | Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor |
| HRP970371A2 (en) | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
| AU3693697A (en) | 1996-07-13 | 1998-02-09 | Glaxo Group Limited | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors |
| ATE227283T1 (en) | 1996-07-13 | 2002-11-15 | Glaxo Group Ltd | CONDENSED HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS |
| KR20000067904A (en) | 1996-07-18 | 2000-11-25 | 디. 제이. 우드, 스피겔 알렌 제이 | Phosphinate Based Inhibitors of Matrix Metalloproteases |
| PL331895A1 (en) | 1996-08-23 | 1999-08-16 | Pfizer | Arylosulphonylamino derivatives of hydroxamic acid |
| CA2277100C (en) | 1997-01-06 | 2005-11-22 | Pfizer Inc. | Cyclic sulfone derivatives |
| CN1113862C (en) | 1997-02-03 | 2003-07-09 | 辉瑞产品公司 | Arylsulfonylamino hydroxamic acid derivs |
| JP2000507975A (en) | 1997-02-07 | 2000-06-27 | ファイザー・インク | N-hydroxy-β-sulfonylpropionamide derivatives and their use as matrix metalloproteinase inhibitors |
| NZ336836A (en) | 1997-02-11 | 2001-02-23 | Pfizer | Arylsulfonyl hydroxamic acid derivatives suitable for a broad range of medicinal treatments |
| JP2002511852A (en) | 1997-05-07 | 2002-04-16 | スージェン・インコーポレーテッド | 2-indolinone derivatives as modulators of protein kinase activity |
| AU734009B2 (en) | 1997-05-30 | 2001-05-31 | Merck & Co., Inc. | Novel angiogenesis inhibitors |
| ATE263147T1 (en) | 1997-08-08 | 2004-04-15 | Pfizer Prod Inc | DERIVATIVES OF ARYLOXYARYLSULFONYLAMINO HYDROXYAMINE ACIDS |
| JP4959049B2 (en) | 1997-08-22 | 2012-06-20 | アストラゼネカ・ユーケイ・リミテッド | Oxyindolylquinazoline derivatives as angiogenesis inhibitors |
| EP1017682A4 (en) | 1997-09-26 | 2000-11-08 | Merck & Co Inc | Novel angiogenesis inhibitors |
| EA005889B1 (en) | 1997-11-11 | 2005-06-30 | Пфайзер Продактс Инк. | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents |
| GB9725782D0 (en) | 1997-12-05 | 1998-02-04 | Pfizer Ltd | Therapeutic agents |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| JPH11236333A (en) | 1997-12-30 | 1999-08-31 | Pfizer Prod Inc | Imidazolin-4-one derivative as anticancer agent |
| GB9800569D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
| GB9800575D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
| GB9801690D0 (en) | 1998-01-27 | 1998-03-25 | Pfizer Ltd | Therapeutic agents |
| AUPP249298A0 (en) | 1998-03-20 | 1998-04-23 | Ag-Gene Australia Limited | Synthetic genes and genetic constructs comprising same I |
| PA8469501A1 (en) | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | HYDROXAMIDES OF THE ACID (4-ARILSULFONILAMINO) -TETRAHIDROPIRAN-4-CARBOXILICO |
| PA8469401A1 (en) | 1998-04-10 | 2000-05-24 | Pfizer Prod Inc | BICYCLE DERIVATIVES OF HYDROXAMIC ACID |
| SK17282000A3 (en) | 1998-05-15 | 2002-04-04 | Imclone Systems Incorporated | Non-radiolabeled protein receptor tyrosine kinase inhibitor |
| TR200003514T2 (en) | 1998-05-29 | 2002-05-21 | Sugen Inc. | Pyrrole substituted 2-indolinone protein kinase inhibitors |
| UA60365C2 (en) | 1998-06-04 | 2003-10-15 | Пфайзер Продактс Інк. | Isothiazole derivatives, a method for preparing thereof, a pharmaceutical composition and a method for treatment of hyperproliferative disease of mammal |
| US6576420B1 (en) | 1998-06-23 | 2003-06-10 | Regents Of The University Of California | Method for early diagnosis of, and determination of prognosis in, cancer |
| US6566131B1 (en) | 2000-10-04 | 2003-05-20 | Isis Pharmaceuticals, Inc. | Antisense modulation of Smad6 expression |
| AU4925199A (en) | 1998-08-27 | 2000-03-21 | Pfizer Products Inc. | Quinolin-2-one derivatives useful as anticancer agents |
| CN1314904A (en) | 1998-08-27 | 2001-09-26 | 辉瑞产品公司 | Alkynyl-substituted quinoline-2-one derivatives useful as anticancer agents |
| US6410323B1 (en) | 1999-08-31 | 2002-06-25 | Isis Pharmaceuticals, Inc. | Antisense modulation of human Rho family gene expression |
| DK1004578T3 (en) | 1998-11-05 | 2004-06-28 | Pfizer Prod Inc | 5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives |
| EP1006113A1 (en) | 1998-12-02 | 2000-06-07 | Pfizer Products Inc. | Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use to inhibit abnormal cell growth |
| US6107091A (en) | 1998-12-03 | 2000-08-22 | Isis Pharmaceuticals Inc. | Antisense inhibition of G-alpha-16 expression |
| US5981732A (en) | 1998-12-04 | 1999-11-09 | Isis Pharmaceuticals Inc. | Antisense modulation of G-alpha-13 expression |
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| UA71945C2 (en) | 1999-01-27 | 2005-01-17 | Pfizer Prod Inc | Substituted bicyclic derivatives being used as anticancer agents |
| JP3270834B2 (en) | 1999-01-27 | 2002-04-02 | ファイザー・プロダクツ・インク | Heteroaromatic bicyclic derivatives useful as anticancer agents |
| SK11002001A3 (en) | 1999-02-11 | 2002-05-09 | Pfizer Products Inc. | Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents |
| US6586447B1 (en) | 1999-04-01 | 2003-07-01 | Pfizer Inc | 3,3-disubstituted-oxindole derivatives useful as anticancer agents |
| US6046321A (en) | 1999-04-09 | 2000-04-04 | Isis Pharmaceuticals Inc. | Antisense modulation of G-alpha-i1 expression |
| GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
| UA75055C2 (en) | 1999-11-30 | 2006-03-15 | Пфайзер Продактс Інк. | Benzoimidazole derivatives being used as antiproliferative agent, pharmaceutical composition based thereon |
| EP1106612B1 (en) | 1999-11-30 | 2004-02-11 | Pfizer Products Inc. | Quinoline derivatives useful for inhibiting farnesyl protein transferase |
| HN2000000266A (en) | 2000-01-21 | 2001-05-21 | Pfizer Prod Inc | ANTI-TARGET COMPOUND AND METHOD OF SEPARATION OF ENANTIOMERS USEFUL TO SYNTHEIZE SUCH COMPOUND. |
| EP1272630A2 (en) | 2000-03-16 | 2003-01-08 | Genetica, Inc. | Methods and compositions for rna interference |
| US6365354B1 (en) | 2000-07-31 | 2002-04-02 | Isis Pharmaceuticals, Inc. | Antisense modulation of lysophospholipase I expression |
| US6566135B1 (en) | 2000-10-04 | 2003-05-20 | Isis Pharmaceuticals, Inc. | Antisense modulation of caspase 6 expression |
| AU2003303094A1 (en) | 2002-12-30 | 2004-08-13 | Exelixis, Inc. | MAT2As AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE |
| US9044432B2 (en) | 2009-12-22 | 2015-06-02 | Ohio State Innovation Foundation | Compositions and methods for cancer detection and treatment |
| WO2012103457A2 (en) | 2011-01-28 | 2012-08-02 | University Of Kentucky | Stilbene analogs and methods of treating cancer |
| WO2014100716A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| JP2016505000A (en) | 2012-12-21 | 2016-02-18 | エピザイム，インコーポレイティド | PRMT5 inhibitors and uses thereof |
| US9221794B2 (en) | 2012-12-21 | 2015-12-29 | Epizyme, Inc. | PRMT5 inhibitors and uses thereof |
| WO2014100730A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Prmt5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof |
| EP2975938A4 (en) | 2013-03-15 | 2017-02-15 | Ohio State Innovation Foundation | Inhibitors of prmt5 and methods of their use |
| TWI533873B (en) | 2014-02-12 | 2016-05-21 | 中央研究院 | Pharmaceutical composition for treating liver diseases |
| CN105039342B (en) | 2015-08-06 | 2017-12-01 | 李家平 | SiRNA and its application of MAT2A gene expressions can be suppressed |
-
2016
- 2016-12-02 EA EA201891304A patent/EA201891304A1/en unknown
- 2016-12-02 US US15/780,494 patent/US20180371551A1/en not_active Abandoned
- 2016-12-02 JP JP2018528729A patent/JP6877429B2/en active Active
- 2016-12-02 WO PCT/US2016/064619 patent/WO2017096165A1/en active Application Filing
- 2016-12-02 CA CA3006743A patent/CA3006743A1/en not_active Abandoned
- 2016-12-02 EP EP16819232.6A patent/EP3383375A1/en not_active Withdrawn
- 2016-12-02 SG SG11201804360XA patent/SG11201804360XA/en unknown
- 2016-12-02 KR KR1020187018814A patent/KR20180100125A/en not_active Application Discontinuation
- 2016-12-02 AU AU2016364855A patent/AU2016364855B2/en active Active
- 2016-12-02 MX MX2018006781A patent/MX2018006781A/en unknown
- 2016-12-02 CN CN201680080863.1A patent/CN108601752A/en active Pending
-
2018
- 2018-06-03 IL IL259773A patent/IL259773A/en unknown
-
2021
- 2021-03-10 JP JP2021037941A patent/JP2021098736A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL259773A (en) | 2018-07-31 |
| EA201891304A1 (en) | 2019-01-31 |
| CA3006743A1 (en) | 2017-06-08 |
| JP6877429B2 (en) | 2021-05-26 |
| WO2017096165A1 (en) | 2017-06-08 |
| KR20180100125A (en) | 2018-09-07 |
| CN108601752A (en) | 2018-09-28 |
| US20180371551A1 (en) | 2018-12-27 |
| AU2016364855A1 (en) | 2018-07-05 |
| EP3383375A1 (en) | 2018-10-10 |
| MX2018006781A (en) | 2018-11-09 |
| JP2018537473A (en) | 2018-12-20 |
| AU2016364855B2 (en) | 2019-08-29 |
| JP2021098736A (en) | 2021-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201804360XA (en) | Mat2a inhibitors for treating mtap null cancer | |
| SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
| SG11201901126UA (en) | Combination therapy for cancer | |
| SG11201808762XA (en) | Diagnostic methods for patient specific therapeutic decision making in cancer care | |
| SG11201903928WA (en) | Mesenchymal stem cells populations, their products, and use thereof | |
| SG11201810162PA (en) | Polynucleotides encoding citrin for the treatment of citrullinemia type 2 | |
| SG11201903155XA (en) | Pharmaceutical compounds | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201808125RA (en) | Methods for solid tumor treatment | |
| SG11201805253SA (en) | Compositions and methods related to multimodal therapeutic cell systems for cancer indications | |
| SG11201901747VA (en) | Inhibitors of cellular metabolic processes | |
| SG11201900799XA (en) | Pyridopyrimdinone cdk2/4/6 inhibitors | |
| SG11201804375WA (en) | Compositions and methods for internalizing enzymes | |
| SG11201806322QA (en) | Maytansinoid derivatives, conjugates thereof, and methods of use | |
| SG11201804312RA (en) | Microbubble-chemotherapeutic agent complex for sonodynamic therapy | |
| SG11201909303TA (en) | Point of delivery cold slurry generation | |
| SG11201906386XA (en) | Combination therapy involving diaryl macrocyclic compounds | |
| SG11201901996UA (en) | Formulations of ( r)-2-amino-3-phenylpropyl carbamate | |
| SG11201805385QA (en) | Bromodomain and extra-terminal protein inhibitor combination therapy | |
| SG11201903032SA (en) | Methods and compositions related to nk cell and anti-pdl1 cancer therapies | |
| SG11201909064RA (en) | Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer | |
| SG11201909837YA (en) | Methods for treating lung disorders | |
| SG11201808713YA (en) | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier |